iSERA Lifesciences quarterly results and financials

iSERA Lifesciences (BSE 534920)₹143.900.00%(9 Nov 2026 close)Computers - Software & Consulting

Key facts

In the Jun 2026 quarter (standalone), iSERA Lifesciences reported sales of ₹0 Cr and net profit of −₹0.35 Cr. For the year to Mar 2026, sales were ₹1.35 Cr and net profit ₹0.27 Cr.

Sales (Jun 2026): ₹0 Cr
Net profit (Jun 2026): −₹0.35 Cr
Sales (FY Mar 2026): ₹1.35 Cr
Net profit (FY Mar 2026): ₹0.27 Cr
EPS (Jun 2026): ₹−0.39
Borrowings (Mar 2026): ₹1.66 Cr

Company filings, standalone accounts; latest reported quarter Jun 2026

iSERA Lifesciences quarterly results

₹ crore unless stated; each column is a quarter.

iSERA Lifesciences Quarterly results
	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.18	1.15	0.00
Expenses	0.01	0.00	0.06	0.00	0.00	0.06	0.03	0.01	0.00	0.46	0.58	0.33
Operating Profit	−0.03	−0.02	−0.08	−0.02	−0.02	−0.08	−0.05	−0.03	0.00	−0.29	0.58	−0.35
OPM %	—	—	—	—	—	—	—	—	—	−147.3%	49.2%	—
Other Income	0.00	0.00	0.00	0.00	0.00	0.00	0.26	0.00	0.00	0.00	0.05	0.00
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Profit before tax	−0.01	0.00	−0.06	0.00	0.00	−0.06	0.22	−0.01	0.00	−0.27	0.62	−0.33
Tax %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	12.8%	0.0%
Net Profit	−0.03	−0.02	−0.08	−0.02	−0.02	−0.08	0.24	−0.03	0.02	−0.29	0.56	−0.35
EPS (Rs)	0.00	0.00	−0.07	0.00	0.00	−0.07	0.26	−0.01	0.00	−0.32	0.64	−0.39

iSERA Lifesciences profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

iSERA Lifesciences Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	25.41	21.29	28.80	12.25	2.12	2.12	0.00	0.00	0.00	0.00	1.35	1.33
Expenses	25.07	20.85	28.35	11.93	2.18	0.18	0.10	0.10	0.08	0.12	1.08	1.37
Operating Profit	0.37	0.45	0.47	0.33	−0.07	1.95	−0.12	−0.12	−0.10	−0.14	0.28	−0.06
OPM %	1.4%	2.1%	1.6%	2.6%	−2.8%	91.1%	—	—	—	—	19.9%	−4.5%
Other Income	−12.56	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.26	0.06	0.05
Interest	0.15	0.19	0.26	0.22	0.21	0.01	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation	0.09	0.22	0.16	0.09	0.13	0.13	0.00	0.00	0.00	0.00	0.00	0.00
Profit before tax	−12.46	0.02	0.03	0.00	−0.39	1.79	−0.10	−0.10	−0.08	0.13	0.33	0.02
Tax %	0.4%	100.0%	25.1%	200.1%	5.0%	1.1%	0.0%	0.0%	0.0%	0.0%	23.6%	—
Exceptional items	−12.97	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
Net Profit	−12.55	0.00	0.05	−0.03	−0.43	1.79	−0.12	−0.12	−0.10	0.15	0.27	−0.06
EPS (Rs)	−0.45	0.00	0.00	0.00	−0.01	0.05	0.00	0.00	−0.10	0.16	0.30	−0.07
Dividend payout %	0.0%	—	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—

iSERA Lifesciences balance sheet

₹ crore, at each year end.

iSERA Lifesciences Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	10.60	10.60	10.61	10.61	10.60	10.60	10.60	0.30	0.30	0.32	0.32	8.40
Reserves	2.43	−10.08	−10.07	−10.02	−10.05	−10.47	−10.70	−0.31	−0.42	−0.54	−0.42	−0.16
Borrowings	4.97	6.15	6.83	7.50	7.53	6.56	2.02	0.00	0.13	0.18	1.61	1.66
Other Liabilities	2.53	4.59	5.54	8.14	4.10	3.79	2.58	0.01	0.03	0.09	0.04	0.64
Total Liabilities	20.53	11.26	12.91	16.23	12.18	10.48	4.50	0.00	0.04	0.05	1.55	10.54
Fixed Assets	6.67	0.49	0.45	0.46	0.76	0.63	0.44	0.00	0.00	0.00	0.00	0.00
CWIP	1.95	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	4.18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	7.73	10.77	12.46	15.77	11.42	9.85	4.06	0.00	0.04	0.05	1.55	10.54
Trade receivables	5.73	8.56	10.18	14.05	9.98	8.55	2.90	0.00	0.00	0.00	0.30	1.19
Cash & equivalents	0.05	0.04	0.02	0.02	0.02	0.02	0.00	0.00	0.00	0.00	0.03	2.88
Total Assets	20.53	11.26	12.91	16.23	12.18	10.48	4.50	0.00	0.04	0.05	1.55	10.54

iSERA Lifesciences cash flow

₹ crore, for each year.

iSERA Lifesciences Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	0.49	0.80	−0.62	−0.50	0.33	0.96	4.44	−0.29	−0.11	−0.05	−1.39	−5.34
Cash from investing activity	−1.15	−0.39	−0.15	−0.15	−0.37	0.00	0.09	0.00	0.00	0.00	0.00	0.05
Cash from financing activity	0.70	−0.43	0.78	0.67	0.05	−0.98	−4.56	0.31	0.14	0.07	1.43	8.15
Net cash flow	0.03	0.00	−0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	2.84
Capex	1.27	0.39	0.15	0.15	0.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Free cash flow	−0.79	0.40	−0.80	−0.66	−0.03	0.96	4.54	−0.29	−0.13	−0.05	−1.39	−5.34
CFO / OP %	80.9%	225.0%	−143.0%	−109.0%	111.9%	−1,650.0%	228.9%	272.9%	109.0%	67.0%	1,062.0%	−1,952.0%

iSERA Lifesciences ratios

Working-capital days and returns, by year.

iSERA Lifesciences Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2025	Mar 2026
Debtor days	194	124	176	179	298	1,471	500	—	—	323
Inventory days	—	—	0	0	0	0	—	—	—	—
Cash conversion cycle	194	124	176	179	298	1,471	500	—	—	323
Working capital days	174	65	92	74	170	1,042	260	—	—	215
ROCE %	0.7%	2.3%	3.3%	4.1%	3.0%	−2.4%	42.5%	−11.5%	19.1%	6.0%

iSERA Lifesciences: frequently asked questions

What are the latest quarterly results of iSERA Lifesciences?

For the Jun 2026 quarter, iSERA Lifesciences reported sales of ₹0 Cr and net profit of −₹0.35 Cr.

What is the annual revenue of iSERA Lifesciences?

iSERA Lifesciences' sales for the year to Mar 2026 were ₹1.35 Cr; over the last twelve months they were ₹1.33 Cr.

What is the net profit of iSERA Lifesciences?

Net profit for the year to Mar 2026 was ₹0.27 Cr, and −₹0.06 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−0.07.

How much debt does iSERA Lifesciences have?

iSERA Lifesciences reported borrowings of ₹1.66 Cr at Mar 2026, against cash and equivalents of ₹2.88 Cr.

What is the free cash flow of iSERA Lifesciences?

Cash from operations was −₹5.34 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹5.34 Cr.

Loading…